Erwan Vo-Quang , Annalice Gandini , Valerie Taly , Pierre Laurent-Puig , Aziz Zaanan , Julien Taieb
{"title":"Circulating tumor DNA: A new tool to predict recurrence and guide treatment of colorectal cancer","authors":"Erwan Vo-Quang , Annalice Gandini , Valerie Taly , Pierre Laurent-Puig , Aziz Zaanan , Julien Taieb","doi":"10.1016/j.clinre.2025.102611","DOIUrl":null,"url":null,"abstract":"<div><div>Circulating tumor DNA (ctDNA) has emerged as a promising biomarker with diverse applications across different stages of colorectal cancer management. One of its primary roles is as a prognostic biomarker for detecting post-surgical molecular residual disease and predicting recurrence risk. Compared to traditional biomarkers and tissue biopsies, ctDNA provides a minimally invasive, dynamic, and comprehensive representation of tumor burden and molecular heterogeneity. However, challenges persist in standardizing ctDNA testing, improving sensitivity for early-stage disease, and ensuring widespread accessibility. In this review, we explore the biological characteristics of ctDNA, the methodologies for its detection, and its broad clinical applications in both localized and metastatic colorectal cancer.</div></div>","PeriodicalId":10424,"journal":{"name":"Clinics and research in hepatology and gastroenterology","volume":"49 7","pages":"Article 102611"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics and research in hepatology and gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210740125000907","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker with diverse applications across different stages of colorectal cancer management. One of its primary roles is as a prognostic biomarker for detecting post-surgical molecular residual disease and predicting recurrence risk. Compared to traditional biomarkers and tissue biopsies, ctDNA provides a minimally invasive, dynamic, and comprehensive representation of tumor burden and molecular heterogeneity. However, challenges persist in standardizing ctDNA testing, improving sensitivity for early-stage disease, and ensuring widespread accessibility. In this review, we explore the biological characteristics of ctDNA, the methodologies for its detection, and its broad clinical applications in both localized and metastatic colorectal cancer.
期刊介绍:
Clinics and Research in Hepatology and Gastroenterology publishes high-quality original research papers in the field of hepatology and gastroenterology. The editors put the accent on rapid communication of new research and clinical developments and so called "hot topic" issues. Following a clear Editorial line, besides original articles and case reports, each issue features editorials, commentaries and reviews. The journal encourages research and discussion between all those involved in the specialty on an international level. All articles are peer reviewed by international experts, the articles in press are online and indexed in the international databases (Current Contents, Pubmed, Scopus, Science Direct).
Clinics and Research in Hepatology and Gastroenterology is a subscription journal (with optional open access), which allows you to publish your research without any cost to you (unless you proactively chose the open access option). Your article will be available to all researchers around the globe whose institution has a subscription to the journal.